Healthcare / Medical DevicesNasdaqCM
$6.20
-2.33 (-27.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-29.8M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$23M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-227.3%
↓Gross Margin
64.3%
↑Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2016–2025 · 9 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-4793.2%
FCF / Net income
0.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $622489.0 · net income $-46.9M · FCF $-29.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | $622489.00 | $622489.00 | $3.9M | $6.8M | $34.2M | $97.9M | $74.6M | $214974.00 | $39911.00 | $7662.00 | — |
| Net Income | $-46.9M | $-46.9M | $-37.6M | $-35.3M | $-14.2M | $36.7M | $42.5M | $-6.2M | $-6.3M | $-7.0M | $-1.9M |
| EBITDA | $-30.2M | $-30.2M | $-38.7M | $-41.5M | $-10.3M | $46.4M | $41.8M | $-5.8M | $-6.1M | $-4.5M | $-1.7M |
| EPS | -35.25 | -35.25 | -37.22 | -36.00 | -13.50 | 36.90 | 45.60 | -11.10 | — | — | — |
| Gross Margin | 64.3% | 64.3% | 74.5% | 38.6% | 84.0% | 88.2% | 77.7% | 47.7% | 76.5% | 96.1% | — |
| Operating Margin | -5025.5% | -5025.5% | -1023.7% | -626.9% | -33.9% | 47.1% | 55.9% | -2741.6% | -15328.6% | -59567.6% | — |
| Net Margin | -7533.6% | -7533.6% | -961.4% | -518.7% | -41.6% | 37.5% | 57.0% | -2882.0% | -15714.3% | -90827.9% | — |
| Balance Sheet | |||||||||||
| Debt/Equity | 0.06 | 0.06 | 0.04 | 0.03 | 0.00 | — | — | — | -1.80 | — | — |
| Current Ratio | 2.28 | 2.28 | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||
| Free Cash Flow | $-29.8M | $-29.8M | $-29.9M | $-23.4M | $5.1M | $40.4M | $27.4M | $-5.6M | $-4.1M | $-3.3M | $-1.3M |
| Returns | |||||||||||
| ROE | -227.3% | -227.3% | -69.9% | -41.1% | -12.4% | 27.3% | 63.7% | -356.6% | 592.3% | -180.7% | 64.4% |
| Valuation | |||||||||||
| P/B | 0.40 | 0.40 | 0.44 | 0.44 | 0.70 | — | — | — | — | — | — |
| Growth & Yield | |||||||||||
| Revenue Growth | -84.1% | -84.1% | -42.5% | -80.1% | — | 31.3% | 34579.9% | 438.6% | 420.9% | — | — |
| EPS Growth | 5.3% | 5.3% | -3.4% | -166.7% | — | -19.1% | 510.8% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-37.22 → -35.25
Residual
-19.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.